Orchestra BioMed Holdings Inc. has released a corporate presentation highlighting ongoing progress in its proprietary cardiovascular programs, AVIM Therapy and Virtue SAB. The company is actively enrolling patients in pivotal clinical trials targeting major cardiovascular conditions in large, established global markets. Both programs have received FDA Breakthrough Device Designations for specific indications, including uncontrolled hypertension and coronary in-stent restenosis. Orchestra BioMed reports that it is funded through the completion of enrollment in both pivotal trials and the AVIM Therapy primary endpoint data readout. The company has also entered into strategic agreements with partners such as Medtronic, Ligand, Terumo, and Haemonetics, securing a cash runway into the fourth quarter of 2027. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Orchestra Biomed Holdings Inc. published the original content used to generate this news brief on February 05, 2026, and is solely responsible for the information contained therein.